Followers | 57 |
Posts | 11139 |
Boards Moderated | 2 |
Alias Born | 04/25/2012 |
Monday, September 21, 2020 12:25:55 PM
I'm not too worried about it at this moment. The rule doesn't become effective for at least 2 months.
Below is the article and one excerpt. My reading is that $NDTP, in its current state, along with 3,000 other stocks, is going to be relegated to the Grey Market. Anyone else want to peruse this and see what you think?
https://www.sec.gov/news/press-release/2020-212
September 16, 2020 - "The Securities and Exchange Commission today adopted amendments to Exchange Act Rule 15c2-11...
...The Rule will become effective 60 days following publication of the amendments in the Federal Register. The Rule will have a general compliance date that is nine months after the effective date as well as a compliance date that is two years after the effective date regarding provisions to require an issuer’s financial information for the last two fiscal years to be current and publicly available."
https://www.tradersmagazine.com/departments/regulation/exploring-the-investor-impact-of-an-sec-rule-proposal/
"However, under the rule proposal, more than 3,000 “No Information” securities that do not make current information available would no longer be eligible for public quoting. Without an alternative solution, these securities would instead be relegated to the Grey market. Transactions in Grey market securities have no public quote, forcing brokers to source liquidity and pricing primarily over the phone without data-driven technology. Investors would then suffer from the lack of price discovery and broker-dealers’ inability to utilize technology or ensure best execution. Some securities may no longer be traded or cleared by brokers or market makers because of expanded regulatory obligations.
Sophisticated, independent investors willing to take on riskier investments worry that without a regulated electronic trading market, the value of their investments will be depleted, destroying millions in shareholder value."
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM